Nanoparticle-Mediated Immunomodulation in Autoimmune Diseases

Autoimmune diseases arise from inappropriate immune responses against self-antigens, leading to chronic inflammation and tissue damage. Nanoparticle-mediated immunomodulation seeks to restore immune tolerance in a targeted fashion, minimising systemic immunosuppression. By engineering particles at the nanometre scale, researchers can control antigen delivery, release kinetics and cellular uptake. Such platforms may carry self-peptides, nucleic acids, small-molecule immunosuppressants or combinations thereof, and can be designed for passive accumulation in lymphoid tissues or for active targeting of specific cell populations. Key objectives include the expansion of regulatory T cells (Tregs), the induction of tolerogenic antigen-presenting cells (APCs) and the re-education of autoreactive lymphocytes. Material choices range from biodegradable polymers and lipids to inorganic cores, each lending distinct properties such as controlled degradation, surface functionalisation or adjuvant-free assembly. Routes of administration span subcutaneous, intravenous and direct intra-lymph node injection, each influencing biodistribution and immunological outcome. Preclinical studies in models of type 1 diabetes, multiple sclerosis, rheumatoid arthritis and transplant rejection have demonstrated disease amelioration through antigen-specific tolerance. The clinical translation of these technologies holds promise for precision therapies that avert the side effects of broad-spectrum immunosuppression, addressing the rising global burden of autoimmune pathology.

Research from Nature Portfolio

Recent studies have shown that ultra-small degradable microparticles encapsulating self-antigens and the mTOR inhibitor rapamycin, when delivered directly into lymph nodes, generate durable tolerance in preclinical models of type 1 diabetes and islet transplantation. This approach promotes local formation of tolerogenic microdomains, expansion of antigen-specific Tregs and systemic protection without compromising protective immunity. Complementing this strategy, peptide–MHC class II-based nanomedicines displaying tissue-restricted autoantigenic epitopes have been applied to models of liver autoimmunity. These constructs reprogram antigen-experienced CD4+ T cells into regulatory type 1 (TR1) cells, recruit regulatory B cells within the hepatic milieu and suppress pro-inflammatory dendritic and Kupffer cell activity, achieving broad therapeutic efficacy across multiple hepatic autoimmune conditions. Foundational work on erythrocyte-targeted self-antigens has further demonstrated that antigen tethered to aged red blood cells is processed tolerogenically, triggering deletion and anergy of autoreactive T cells and inducing FOXP3+ Tregs that maintain long-term immune tolerance.

Nanoparticle-Mediated Immunomodulation in Autoimmune Diseases publication trend

The graph below shows the total number of articles in nanoparticle-mediated immunomodulation in autoimmune diseases across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle: A submicrometre-sized carrier (typically 1–200 nm) designed for precise delivery of therapeutic cargos to cells or tissues.

Regulatory T cell (Treg): A specialised lymphocyte subset that suppresses immune activation and maintains self-tolerance.

Antigen-presenting cell (APC): A cell (e.g. dendritic cell) that processes and presents antigenic peptides to T cells, guiding their activation or tolerance.

Lipid nanoparticle (LNP): A vesicular delivery system composed of lipids that can encapsulate nucleic acids or drugs for targeted cellular uptake.

Tolerogenic: Describing an agent or environment that promotes immune unresponsiveness to specific antigens, preventing pathological inflammation.

References

1. Engineering the lymph node environment promotes antigen-specific efficacy in type 1 diabetes and islet transplantation. Nature Communications (2023).
2. Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines. Nature Communications (2019).
3. Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. Scientific Reports (2015).
4. Antigen‐specific mRNA lipid nanoparticle platforms for the prevention and treatment of allergy and autoimmune diseases. BMEMat (2023).
5. Biomaterials-Mediated Engineering of the Immune System. Annual Review of Immunology (2023).
6. Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps. Advanced Science (2023).